Item 7.01. Regulation FD Disclosure.

As reported under Item 8.01 of this Current Report on Form 8-K, on January 7, 2021, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") regarding the top-line symptom and sign results from the run-in cohort of its Phase 3 TRANQUILITY Trial in dry eye disease. The Company is holding a conference call on January 7, 2021. A copy of the supplemental presentation which will be referenced during the conference call and posted on the Company's website is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01. Other Events.

On January 7, 2021, the Company issued a press release regarding the top-line symptom and sign results from the run-in cohort of its Phase 3 TRANQUILITY Trial in dry eye disease. The Press Release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.     Description

99.1        Aldeyra Therapeutics, Inc. Presentation dated January 7, 2021.

99.2        Aldeyra Therapeutics, Inc. Press Release dated January 7, 2021.

104       Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses